Vaccine value profile for schistosomiasis.

Autor: Yamey G; Duke Global Health Institute, Duke University, Durham, NC, United States. Electronic address: gavin.yamey@duke.edu., McDade KK; Duke Global Health Institute, Duke University, Durham, NC, United States. Electronic address: kaci.kennedy.mcdade@duke.edu., Anderson RM; Faculty of Medicine, School of Public Health, Imperial College London, London, United Kingdom. Electronic address: roy.anderson@imperial.ac.uk., Bartsch SM; Public Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address: sbartsch1029@gmail.com., Bottazzi ME; National School of Tropical Medicine, Baylor College of Medicine, Texas Children's Hospital Center for Vaccine Development, Houston, TX, United States. Electronic address: bottazzi@bcm.edu., Diemert D; School of Medicine and Health Sciences, George Washington University, Washington, D.C., United States. Electronic address: ddiemert@gwu.edu., Hotez PJ; National School of Tropical Medicine, Baylor College of Medicine, Texas Children's Hospital Center for Vaccine Development, Houston, TX, United States. Electronic address: hotez@bcm.edu., Lee BY; Public Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address: bruceleemdmba@gmail.com., McManus D; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Don.McManus@qimrberghofer.edu.au., Molehin AJ; Department of Microbiology & Immunology, Midwestern University, Glendale, AZ, United States. Electronic address: amoleh@midwestern.edu., Roestenberg M; Leiden University Medical Centre, Leiden, Netherlands. Electronic address: M.Roestenberg@lumc.nl., Rollinson D; Global Schistosomiasis Alliance, London, United Kingdom. Electronic address: d.rollinson@nhm.ac.uk., Siddiqui AA; Center for Tropical Medicine & Infectious Diseases, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, United States. Electronic address: Afzal.Siddiqui@ttuhsc.edu., Tendler M; Laboratory of Research and Development of Anti-Helminth Vaccines, Oswaldo Cruz Institute (Fiocruz), Rio de Janeiro, Brazil. Electronic address: tendlermiriam@gmail.com., Webster JP; Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, United Kingdom. Electronic address: jowebster@rvc.ac.uk., You H; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Hong.You@qimrberghofer.edu.au., Zellweger RM; International Vaccine Institute, Seoul, Korea. Electronic address: raphael.zellweger@ivi.int., Marshall C; World Health Organization, Geneva, Switzerland.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Jul 23, pp. 126020. Date of Electronic Publication: 2024 Jul 23.
DOI: 10.1016/j.vaccine.2024.05.068
Abstrakt: Schistosomiasis is caused by parasitic flatworms (Schistosoma). The disease in humans can be caused by seven different species of Schistosoma: S. mansoni, S. japonicum, S. haematobium, S. malayensis, S. mekongi, S. guineensis and S. intercalatum, as well as by hybrids between species, including livestock schistosome species. People are infected when exposed to infested water and the parasite larvae penetrate the skin. Poor and rural communities are typically the most affected, and the general population who lives in affected areas and is exposed to contaminated water is at risk. Areas with poor access to safe water and adequate sanitation are also at heightened risk. About 236.6 million people required treatment for schistosomiasis in 2019-mostly people living in poor, rural communities, especially fishing and agricultural communities. This 'Vaccine Value Profile' (VVP) for schistosomiasis is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the schistosomiasis VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GY and KKM declare that they have received research funding from the WHO, the Bill & Melinda Gates Foundation (BMGF), The Carnegie Corporation of New York, the United Nations Economic and Social Commission for Asia and the Pacific, the Alliance for Health Policy and Systems Research, and the New Venture Fund. PH declares that he is the inventor and patentholder on vaccines against schistosomiasis which are in clinical trials and/or in development stages AS declares research funding from BMGF, EU/Horizon 2020, the Wellcome Trust, the National Institutes of Health, the RIGHT Foundation, and the Thrasher Foundation. DR declares that he is Director of the Global Schistosomiasis Alliance; consultation for Merck KGaA, which donates drugs for the treatment of schistosomiasis (he receives consulting fees in relation to his role as Director of the Global Schistosomiasis Alliance); and fees as editor of Advances in Parasitology. MT declares research funding from Finep, FIOCRUZ (Brazilian health ministry), Orygen Biotechnology, WHO, and FAPERJ (Rio de Janeiro State Financial Agency); consulting for Orygen Biotechnology and FABP Biotech; support from FIOCRUZ to attend meetings/travel; membership of the Scientific Advisory Board for the Sm14 Schistosomiasis Humanitarian Vaccine; and stock in Biomanguinhos, FIOCRUZ; she is CEO of FABP Biotech (an animal health company). JW declares research funding from the Food and Agriculture Organization of the United Nations, Research England: The Bloomsbury SET, Global Challenges Research Fund: UKRI Collective Fund, and the Biotechnology and Biological Sciences Research Council; she is the Director of the London Centre for NTD Research (unpaid) and the Director/Trustee of Fauna and Flora International (unpaid). HY declares support from the Australian National Health and Medical Research Council (grants APP1194462 and APP1132975).
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: